Sheinfeld, Joel

Publications

Sort by

Co-Author Network

selected publications

Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 8
Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 16
A Laparoscopic Approach is Best for Retroperitoneal Lymph Node Dissection: No. The Journal of urology. 2017 Academic Article GET IT
Times cited: 4
Editorial Comment. Urology. 2016 Comment GET IT
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. Urology. 2016 Academic Article GET IT
Times cited: 39
Editorial Comment. Urology. 2016 Comment GET IT
Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. Urology. 2016 Academic Article GET IT
Times cited: 8
Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. The Journal of urology. 2016 Academic Article GET IT
Times cited: 6
Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 121
The Evolving Management of Patients With Clinical Stage I Seminoma. Urology. 2016 Academic Article GET IT
Times cited: 11
Retroperitoneal Lymph Node Dissection: Anatomical and Technical Considerations from a Cadaveric Study. The Journal of urology. 2016 Academic Article GET IT
Times cited: 13
Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. Urology. 2016 Academic Article GET IT
Times cited: 3
Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 29
Are Some Cases of Somatic Type Malignancy Potentially Avoidable?. The Journal of urology. 2016 Editorial Article GET IT
Therapeutic Application of Percutaneous Peritoneovenous (Denver) Shunt in Treating Chylous Ascites in Cancer Patients. Journal of vascular and interventional radiology : JVIR. 2016 Academic Article GET IT
Times cited: 19
Late Relapse of Testicular Germ Cell Tumors. The Urologic clinics of North America. 2015 Review GET IT
Times cited: 31
Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Review GET IT
Times cited: 10
Testicular Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Academic Article GET IT
Times cited: 93
Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 7
Kidney cancer, version 3.2015. 2015 GET IT
Times cited: 195
Editorial comment. Urology. 2014 Editorial Article GET IT
Times cited: 2
Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. The Journal of urology. 2014 Academic Article GET IT
Times cited: 16
Clinical outcomes of local and metastatic testicular sex cord-stromal tumors. The Journal of urology. 2014 Academic Article GET IT
Times cited: 38
Kidney cancer, version 2.2014. 2014 GET IT
Times cited: 56
Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy. Urology. 2013 Academic Article GET IT
Times cited: 17
Reply: To PMID 24094653. Urology. 2013 Comment GET IT
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer. 2013 Academic Article GET IT
Times cited: 29
Rare de novo germline copy-number variation in testicular cancer. American journal of human genetics. 2012 Academic Article GET IT
Times cited: 16
Testicular cancer. 2012 GET IT
Times cited: 62
Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site. Urology. 2012 Academic Article GET IT
Times cited: 6
Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour. BJU international. 2012 Academic Article GET IT
Times cited: 8
Editorial comment. Urology. 2012 Editorial Article GET IT
Cervical metastasis of germ cell tumors: evaluation, management, complications, and outcomes. The Laryngoscope. 2012 Academic Article GET IT
Times cited: 5
Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Urology. 2012 Academic Article GET IT
Times cited: 22
Environmental toxicology of testicular cancer. Urologic oncology. 2012 Review GET IT
Times cited: 16
Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection. Urology. 2011 Academic Article GET IT
Times cited: 16
The role of lymphadenectomy for testicular cancer: indications, controversies, and complications. The Urologic clinics of North America. 2011 Review GET IT
Times cited: 11
Introduction: International consultation on urologic diseases: testicular cancer: Societe Internationale d'Urologie/International Consultation on Urologic Diseases Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology. 2011 Article GET IT
Kidney cancer. 2011 GET IT
Times cited: 82
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer. 2011 Academic Article GET IT
Times cited: 51
Retroperitoneal histologic findings of patients with elevated serum alpha-fetoprotein and pure seminoma at orchiectomy. Urology. 2011 Academic Article GET IT
Times cited: 9
Postchemotherapy surgery for germ cell tumors of the testis. Current opinion in oncology. 2011 Review GET IT
Times cited: 3
Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update. Urology. 2011 Academic Article GET IT
Times cited: 11
The management of subcentimeter residual mass in NSGCT: pcRPLND vs. observation. Urologic oncology. 2011 Academic Article GET IT
Times cited: 11
Contemporary lymph node counts during primary retroperitoneal lymph node dissection. Urology. 2010 Academic Article GET IT
Times cited: 12
Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. Cancer. 2010 Academic Article GET IT
Times cited: 24
The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer. Urology. 2010 Academic Article GET IT
Times cited: 40
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 176
Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor. Indian journal of urology : IJU : journal of the Urological Society of India. 2010 Academic Article GET IT
Times cited: 2
Retroperitoneal lymph node dissection after chemotherapy. BJU international. 2009 Review GET IT
Times cited: 29
Retroperitoneal lymph node dissection: reassessment of modified templates. BJU international. 2009 Review GET IT
Times cited: 23
Challenges in testicular cancer management. World journal of urology. 2009 Editorial Article GET IT
NCCN clinical practice guidelines in oncology: kidney cancer. 2009 GET IT
Times cited: 163
NCCN clinical practice guidelines in oncology: testicular cancer. 2009 GET IT
Times cited: 97
Management of post-chemotherapy extra-retroperitoneal residual masses. World journal of urology. 2009 Review GET IT
Times cited: 22
Critical elements in fellowship training. Urologic oncology. 2009 Academic Article GET IT
Times cited: 4
Preservation of ejaculation in patients undergoing nerve-sparing postchemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer. Urology. 2008 Academic Article GET IT
Times cited: 89
Clinical outcome and predictors of survival in late relapse of germ cell tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 79
Retroperitoneal lymph node dissection (RPLND). Gynecologic oncology. 2008 Academic Article GET IT
Times cited: 11
Stage I testicular cancer management and necessity for surgical expertise. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Editorial Article GET IT
Times cited: 12
The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. Cancer. 2008 Academic Article GET IT
Times cited: 19
Medical treatment of advanced testicular cancer. JAMA. 2008 Review GET IT
Times cited: 293
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 98
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 74
Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 117
Association between sarcoidosis and testicular carcinoma: a diagnostic pitfall. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 2007 Review GET IT
Times cited: 49
Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 2007 Academic Article GET IT
Times cited: 21
Adult and pediatric testicular teratoma. The Urologic clinics of North America. 2007 Review GET IT
Times cited: 33
Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. BJU international. 2007 Academic Article GET IT
Times cited: 27
Reoperative retroperitoneal surgery. The Urologic clinics of North America. 2007 Review GET IT
Times cited: 7
Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. The Journal of urology. 2007 Academic Article GET IT
Times cited: 83
Mapping studies and modified templates in nonseminomatous germ cell tumors. Nature clinical practice. Urology. 2007 Academic Article GET IT
Times cited: 5
Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007 Academic Article GET IT
Times cited: 56
Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 80
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 108
Adjunctive nephrectomy at post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer. The Journal of urology. 2006 Academic Article GET IT
Times cited: 42
Kidney cancer. Clinical practice guidelines in oncology. 2006 GET IT
Times cited: 7
Testicular cancer. Clinical practice guidelines in oncology. 2006 GET IT
Times cited: 17
Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. The Journal of urology. 2006 Academic Article GET IT
Times cited: 63
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 151
Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 95
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 71
Germ cell tumors of the testis. Annals of surgical oncology. 2005 Review GET IT
Times cited: 49
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 327
Management of patients with low-stage nonseminomatous germ cell testicular cancer. Current treatment options in oncology. 2005 Review GET IT
Times cited: 31
Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. The Journal of urology. 2005 Academic Article GET IT
Times cited: 91
The current status of laparoscopic retroperitoneal lymph node dissection for non-seminomatous germ-cell tumors. Nature clinical practice. Urology. 2005 Review GET IT
Times cited: 13
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 168
Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: a case report and review of the literature. Gynecologic oncology. 2005 Review GET IT
Times cited: 16
Kidney cancer. Clinical practice guidelines. 2005 GET IT
Times cited: 1
Late relapse of testicular germ cell tumors. Urologic oncology. 2005 Review GET IT
Times cited: 33
Testicular cancer. Clinical practice guidelines. 2005 GET IT
Times cited: 4
Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. The Journal of urology. 2004 Academic Article GET IT
Times cited: 84
Editorial: predicting necrosis after chemotherapy for advanced nonseminomatous germ cell tumor-surrogate end points, decreasing morbidity and patient outcome. The Journal of urology. 2004 Editorial Article GET IT
Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor. The Journal of urology. 2004 Academic Article GET IT
Times cited: 9
Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors. Investigational new drugs. 2004 Academic Article GET IT
Times cited: 12
Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 75
The role of retroperitoneal lymph node dissection in the management of testicular cancer. Urologic oncology. 2004 Review GET IT
Times cited: 66
Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. The Journal of urology. 2004 Academic Article GET IT
Times cited: 38
Chemotherapy for teratoma with malignant transformation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 175
Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. Urology. 2003 Review GET IT
Times cited: 30
Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups. The Urologic clinics of North America. 2003 Review GET IT
Times cited: 13
Poor-risk testicular cancer and high-dose chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Editorial Article GET IT
Times cited: 4
Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumors. The Journal of urology. 2003 Academic Article GET IT
Times cited: 47
Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology. 2003 Academic Article GET IT
Times cited: 77
Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. The Journal of urology. 2003 Academic Article GET IT
Times cited: 19
Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001. The Journal of urology. 2003 Academic Article GET IT
Times cited: 72
Recommendations of follow-up after treatment of germ cell tumors. Seminars in oncology. 2003 Review GET IT
Times cited: 16
The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours. BJU international. 2003 Academic Article GET IT
Times cited: 41
Risks of the uncontrolled retroperitoneum. Annals of surgical oncology. 2003 Editorial Article GET IT
Times cited: 24
Is there an increased incidence of contralateral testicular cancer in patients with intratesticular microlithiasis?. AJR. American journal of roentgenology. 2003 Academic Article GET IT
Times cited: 39
The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies. Seminars in urologic oncology. 2002 Review GET IT
Times cited: 39
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 149
Paracolic recurrence: the importance of wide excision of the spermatic cord at retroperitoneal lymph node dissection. The Journal of urology. 2002 Academic Article GET IT
Times cited: 15
Salvage chemotherapy for patients with advanced pure seminoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 51
Testicular microlithiasis: what is its association with testicular cancer?. Radiology. 2001 Academic Article GET IT
Times cited: 119
When is partial ureterectomy acceptable for transitional-cell carcinoma of the ureter?. Journal of endourology. 2001 Review GET IT
Times cited: 29
Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 90
Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 235
Abnormal testis at US in patients after orchiectomy for testicular neoplasm. Radiology. 2000 Academic Article GET IT
Times cited: 5
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Times cited: 165
Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer. Journal of the National Cancer Institute. 1999 Editorial Article GET IT
Times cited: 33
NCCN practice guidelines for kidney cancer. National Comprehensive Cancer Network. 1998 GET IT
Times cited: 2
NCCN practice guidelines for testicular cancer. National Comprehensive Cancer Network. 1998 GET IT
Times cited: 10
Role of surgery in management of germ cell tumor. Seminars in oncology. 1998 Review GET IT
Times cited: 55
Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. 1998 GET IT
Times cited: 322
Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology. 1997 Academic Article GET IT
Times cited: 117
Adjuvant chemotherapy for testicular cancer. Surgical oncology clinics of North America. 1997 Review GET IT
Times cited: 5
Is biopsy of the contralateral testis necessary in patients with germ cell tumors?. The Journal of urology. 1997 Review GET IT
Times cited: 65
Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology. 1997 Academic Article GET IT
Times cited: 166
Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. British journal of urology. 1997 Academic Article GET IT
Times cited: 37
Surgery for a post-chemotherapy residual mass in seminoma. The Journal of urology. 1997 Review GET IT
Times cited: 137
The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology. 1997 Academic Article GET IT
Times cited: 80
Genetic studies and molecular markers of bladder cancer. Seminars in surgical oncology. 1997 Review GET IT
Times cited: 53
Molecular and immunopathology studies of oncogenes and tumor-suppressor genes in bladder cancer. World journal of urology. 1997 Review GET IT
Times cited: 14
Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. The Journal of urology. 1996 Academic Article GET IT
Times cited: 52
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Times cited: 81
Defining new standards for adjuvant therapy of testis cancer: a reply. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Letter GET IT
Times cited: 2
Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. The Journal of urology. 1996 Academic Article GET IT
Times cited: 46
Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995 Academic Article GET IT
Times cited: 62
Prostate cancer. The Journal of urology. 1995 Editorial Article GET IT
Times cited: 1
Urinary reconstruction and diversion. The Journal of urology. 1995 Editorial Article GET IT
Times cited: 1
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. The Journal of urology. 1995 Academic Article GET IT
Times cited: 207
p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer research. 1995 Academic Article GET IT
Times cited: 358
Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. British journal of urology. 1994 Academic Article GET IT
Times cited: 35
Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. The Journal of urology. 1994 Academic Article GET IT
Times cited: 188
Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence. The Journal of urology. 1994 Academic Article GET IT
Times cited: 24
Nonseminomatous germ cell tumors of the testis: current concepts and controversies. Urology. 1994 Review GET IT
Times cited: 32
The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. The Memorial Sloan-Kettering Cancer Center experience. Cancer. 1994 Academic Article GET IT
Times cited: 83
Bladder cancer: advances in biology and treatment. Critical reviews in oncology/hematology. 1994 Review GET IT
Times cited: 8
Enhanced detection of bladder cancer in urine cytology with Lewis X, M344 and 19A211 antigens. Acta cytologica. 1994 Academic Article GET IT
Ha-ras codon 12 mutation in papillary tumors of the urinary-bladder - a retrospective study. International journal of oncology. 1994 Academic Article GET IT
Tobacco smoking, occupation, and p53 nuclear overexpression in early stage bladder cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1994 Academic Article GET IT
Times cited: 49
Biological markers of prognosis in transitional cell carcinoma of the bladder: current concepts. Seminars in urology. 1993 Review GET IT
Times cited: 22
P53 nuclear overexpression and disease progression in ta-bladder carcinoma. International journal of oncology. 1993 Academic Article GET IT
Times cited: 40
Management of the postchemotherapy residual mass. The Urologic clinics of North America. 1993 Review GET IT
Times cited: 35
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 501
High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. Cancer. 1992 Academic Article GET IT
Times cited: 114
Blood group antigens in normal and neoplastic urothelium. Journal of cellular biochemistry. Supplement. 1992 Review GET IT
Times cited: 15
Cell surface differentiation antigens of normal urothelium and bladder tumors. Seminars in surgical oncology. 1992 Review GET IT
Times cited: 8
Expression of blood group antigens in bladder cancer: current concepts. Seminars in surgical oncology. 1992 Review GET IT
Times cited: 15
Intervention strategies for chemoprevention of bladder cancer. Journal of cellular biochemistry. Supplement. 1992 Academic Article GET IT
Times cited: 1
Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer. 1991 Academic Article GET IT
Times cited: 142
The T1 bladder tumor. Seminars in urology. 1990 Review GET IT
Times cited: 79
Association of type 1 blood group antigens with urinary tract infections in children with genitourinary structural abnormalities. The Journal of urology. 1990 Academic Article GET IT
Times cited: 8
Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. The Journal of urology. 1990 Academic Article GET IT
Times cited: 73
Recent diagnostic modalities for bladder cancer. Immunology series. 1990 Review GET IT
Times cited: 1
Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. The New England journal of medicine. 1989 Academic Article GET IT
Times cited: 203
Blood group-related antigens in human kidney: modulation of Lewis determinants in renal cell carcinoma. Cancer research. 1989 Academic Article GET IT
Times cited: 45
Metaplastic cystitis complicated with Von Brunn nests, cystitis cystica, and intestinal type of glandular metaplasia. 1988 GET IT
Times cited: 9
Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma. Cancer research. 1988 Academic Article GET IT
Times cited: 75
Octoson imaging in pediatric urology. Urology. 1987 Academic Article GET IT
Voiding dysfunction in tertiary syphilis. 1987 GET IT
Times cited: 5
Perinephric abscess: current concepts. The Journal of urology. 1987 Academic Article GET IT
Times cited: 54
The effect of graded unilateral testicular biopsy on the reproductive capacity of male rats. The Journal of urology. 1986 Academic Article GET IT
Times cited: 9
Penile tourniquet injury due to a coil of hair. 1985 GET IT
Times cited: 31
Renal trauma: evaluation by computerized tomography. The Journal of urology. 1985 Academic Article GET IT
Times cited: 14
Selective pre-transplant nephrectomy: indications and perioperative management. The Journal of urology. 1985 Academic Article GET IT
Times cited: 18
Direct fibrinolytic therapy for renal vein thrombosis: radiographic followup. 1984 GET IT
Times cited: 8
Male infertility due to communicating bilateral varicoceles. 1984 GET IT
Times cited: 1
Ultrafiltration evidence of ion binding by macromolecules in urine. Investigative urology. 1978 Academic Article GET IT
Times cited: 4

more ...

less ...

Background

education and training

M.D., University of Florida College of Medicine 1981
B.A., Cornell University 1976

Contact

full name

Joel Sheinfeld

VIVO Weill Cornell Medical College

Joel Sheinfeld Professor of Urology

Publications

selected publications

Background

education and training

Contact

full name